Abbott has received approval from Health Canada for the Xience V Everolimus Eluting Coronary Stent System, for the treatment of coronary artery disease (CAD). Reportedly, Xience V is
UCB and Novartis have entered into a licensing agreement for cardiovascular and diabetes products in Germany. Under the agreement, UCB has extended commercial rights for the German market
The FDA is reviewing adverse event reports of liver injury in patients taking the weight loss drug orlistat, marketed as the prescription drug, Xenical and the over-the-counter medication,
Osteologix has reported that the Japan Patent Office (JPO) has issued a decision to grant a patent for application number 2006-504379: Treating Cartilage/Bone Conditions with Water-Soluble Strontium Salts.
Resolvyx has reported positive data from a phase 2 clinical study evaluating RX-10045, a resolvin administered as a topical eye drop for the treatment of patients with chronic
Karolinska has reported that Xspray Microparticles has launched a GMP production facility in Malmo, Sweden. In addition to offering particle development and characterization services, XSpray can now provide
Perrigo has acquired 85% stake of Vedants Drugs and Fine Chemicals. The company now plans to move its active pharmaceutical ingredients (API) manufacturing units from Israel and Germany
Roche has sealed a deal with Pontifax Management to build a R&D pipeline in Israel. Under the agreement, Pontifax will help Roche to identify and invest in Israeli
Orexo has reported net revenues of SEK29.6m for the second quarter of 2009, compared to SEK56.2m for the same period in 2008. The company has also reported a
The FDA has accepted and filed for review the Cell Therapeutics’ (CTI) New Drug Application (NDA) for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin’s lymphoma (NHL).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.